Selank and Semax are two synthetic peptides developed in Russia and studied for anxiolytic and neuroprotective properties respectively, with largely separate literatures despite frequent pairing.
Key Takeaways
- Semax is a fragment of adrenocorticotropic hormone studied for neuroprotection and cognitive effects.
- Both are most often studied by intranasal administration, which bypasses first-pass metabolism but introduces dosing variability.
- The most defensible framing is that both compounds have a real but geographically concentrated and only partially replicated literature.
Different origins, different claims
Semax is a fragment of adrenocorticotropic hormone studied for neuroprotection and cognitive effects. Selank is a tuftsin analogue developed for anxiolytic activity. They are often sold together, but their evidence bases should be evaluated separately.
Proposed mechanisms
Semax work discusses BDNF upregulation and modulation of monoamine systems. Selank literature focuses on GABAergic modulation and on gene-expression changes in brain tissue. Neither has a settled mechanism, and both rely substantially on rodent behavioural endpoints.
For related mechanism work, see GHK-Cu copper peptide.
Route and pharmacokinetics
Both are most often studied by intranasal administration, which bypasses first-pass metabolism but introduces dosing variability. Nasal peptide bioavailability is generally low and formulation-dependent, a point frequently omitted from secondary summaries.
Clinical evidence quality
There are human studies, mostly small and largely from the originating research tradition, with limited independent confirmation. Effect sizes in anxiety and cognitive endpoints are reported but have not been robustly replicated in large multicentre trials.
How to assess the claims
The most defensible framing is that both compounds have a real but geographically concentrated and only partially replicated literature. That is a different statement from either ‘well established’ or ‘no evidence’.
Experimental Conditions and Practical Setup
Behavioural work uses standard rodent tests with the peptide given intranasally, and the critical variable is the delivered volume and the deposition site rather than the nominal dose. Because nasal bioavailability is low and variable, studies that report only a nominal dose without a device description cannot be compared with one another.
Why intranasal study results are hard to compare
| Variable | Impact | Reporting requirement |
|---|---|---|
| Device and plume | Determines deposition site | State device and spray geometry |
| Formulation volume | Affects drainage versus absorption | State volume per nostril |
| Mucociliary clearance | Limits residence time | State sampling timepoints |
| Nominal versus delivered dose | Often differ substantially | Report both where measurable |
Practical Notes for the Bench
- Evaluate Selank and Semax evidence separately, not as a pair.
- Account for intranasal dosing variability in any comparison.
- Check whether human studies come from independent research groups.
Frequently Asked Questions
Are Selank and Semax the same thing?
No. Semax is an ACTH fragment studied for neuroprotection; Selank is a tuftsin analogue studied for anxiolytic effects.
Why intranasal administration?
It avoids first-pass metabolism, though nasal bioavailability for peptides is generally low and highly formulation-dependent.
How strong is the human data?
Human studies exist but are mostly small and geographically concentrated, with limited independent replication.
Are the two peptides interchangeable in research?
No. They have different origins and different proposed mechanisms, and their literatures should be evaluated separately even though they are frequently discussed together.
Related Reading
- GHK-Cu copper peptide
- humanin peptide research
- TB-500 thymosin beta-4
- calculating peptide dose
- exorphin opioid peptides
References & Further Reading
- Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020. PubMed 32342318
- Slominsky PA et al. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Dokl Biol Sci. 2017. PubMed 28702721
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
The notes below reflect common laboratory practice and open literature. They are not clinical recommendations, and peptides discussed are research materials unless stated otherwise.
Reviewed by Dr. Marcus Feld, Molecular Pharmacology, In Vitro Models.